Regimmune Corporation, a Tokyo, Japan-based biotechnology company, closed a $9.2m Series D financing.
The round was led by Japan Asia Investment Corporation (JAIC) and Nippon Venture Capital Corp (NVCC), with participation from new investors Mizuho Capital, Nissei Insurance, KSP, Inc., the core business entity that operates the Kanagawa Science Park, and Mitsui-Sumitomo Insurance, as well as existing investors SMBC Venture Capital Co., Ltd., and Mitsubishi UFJ Bank Capital.
The company intends to use the funds to support early stage product development.
Led by Haru Morita, President and Chief Executive Officer, Regimmune focuses on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It completed a Phase I study of RGI-2001 for Graft versus Host Disease (GvHD) and recently initiated a Phase II clinical trial for RGI-2001.
The company is also developing a range of pipeline products, including its RGI-1000 series for allergy, RGI-3100 series for type 1 diabetes, products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners.
Regimmune has a US operation in San Francisco, California.